Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Retained Earnings (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Retained Earnings for 7 consecutive years, with -$369.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Retained Earnings fell 12.46% to -$369.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$369.2 million, a 12.46% decrease, with the full-year FY2023 number at -$337.6 million, down 16.91% from a year prior.
  • Retained Earnings was -$369.2 million for Q3 2024 at Actinium Pharmaceuticals, down from -$357.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$236.3 million in Q1 2021 to a low of -$369.2 million in Q3 2024.
  • A 4-year average of -$295.4 million and a median of -$288.8 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: dropped 10.4% in 2022, then fell 18.03% in 2023.
  • Actinium Pharmaceuticals' Retained Earnings stood at -$255.7 million in 2021, then decreased by 12.91% to -$288.8 million in 2022, then dropped by 16.91% to -$337.6 million in 2023, then fell by 9.36% to -$369.2 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Retained Earnings are -$369.2 million (Q3 2024), -$357.6 million (Q2 2024), and -$346.3 million (Q1 2024).